358 related articles for article (PubMed ID: 14734884)
1. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
[TBL] [Abstract][Full Text] [Related]
2. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
[TBL] [Abstract][Full Text] [Related]
3. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.
Kullberg-Lindh C; Saalman R; Olausson M; Herlenius G; Lindh M
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28039929
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
Kamei H; Ito Y; Kawada J; Ogiso S; Onishi Y; Komagome M; Kurata N; Ogura Y
Transpl Infect Dis; 2018 Aug; 20(4):e12911. PubMed ID: 29677384
[TBL] [Abstract][Full Text] [Related]
6. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
Soriano-López DP; Alcántar-Fierros JM; Hernández-Plata JA; González-Jorge AL; Velázquez-Ramos S; Flores-Hernández MA; Fuentes V; Castañeda P; Nieto J; Sánchez JL; López B; Valencia-Mayoral P; Varela-Fascinetto G
Transplant Proc; 2016 Mar; 48(2):654-7. PubMed ID: 27110023
[TBL] [Abstract][Full Text] [Related]
7. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
8. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
9. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
[TBL] [Abstract][Full Text] [Related]
10. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
Lee TC; Savoldo B; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Barshes NR; Scott JD; Bristow LJ; O'Mahony CA; Goss JA
Am J Transplant; 2005 Sep; 5(9):2222-8. PubMed ID: 16095501
[TBL] [Abstract][Full Text] [Related]
11. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
12. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
13. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
[TBL] [Abstract][Full Text] [Related]
14. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
[TBL] [Abstract][Full Text] [Related]
16. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome.
Holmes RD; Orban-Eller K; Karrer FR; Rowe DT; Narkewicz MR; Sokol RJ
Transplantation; 2002 Aug; 74(3):367-72. PubMed ID: 12177616
[TBL] [Abstract][Full Text] [Related]
17. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
[TBL] [Abstract][Full Text] [Related]
18. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
[TBL] [Abstract][Full Text] [Related]
19. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
[TBL] [Abstract][Full Text] [Related]
20. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation.
Gridelli B; Spada M; Riva S; Colledan M; Segalin A; Lucianetti A; Sonzogni A; Furione M; Baldanti F; Torre G
Transpl Int; 2000; 13 Suppl 1():S399-401. PubMed ID: 11112041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
